A Randomised Phase II Double-blinded Placebo-controlled Trial of Intravenous Immunoglobulins and Rituximab in Patients with Antibody-associated Psychosis (SINAPPS2)
Latest Information Update: 04 Apr 2025
At a glance
- Drugs Immunoglobulin G (Primary) ; Rituximab (Primary)
- Indications Psychotic disorders
- Focus Therapeutic Use
- Acronyms SINAPPS2
Most Recent Events
- 30 Mar 2025 Planned End Date changed from 31 Mar 2026 to 31 Mar 2027.
- 30 Mar 2025 Planned primary completion date changed from 31 Mar 2026 to 31 Mar 2027.
- 26 Jan 2024 Planned End Date changed from 31 Mar 2024 to 31 Mar 2026.